Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$2.00
-19.7%
$2.19
$1.30
$13.20
$2.64M0.542.34 million shs566,976 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$3.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
NexImmune, Inc. stock logo
NEXI
NexImmune
$3.32
+6.4%
$4.91
$1.25
$28.69
$4.55M2.0335,968 shs37,434 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-19.68%+33.33%-9.09%-10.31%-75.76%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
NexImmune, Inc. stock logo
NEXI
NexImmune
+6.41%-2.64%-34.26%-73.65%-57.16%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
1.6466 of 5 stars
3.33.00.00.02.80.00.6
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.50
Moderate Buy$11.00450.00% Upside
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/A

Current Analyst Ratings

Latest INNVD, CYCC, LCI, and NEXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $11.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$420K6.29N/AN/A$0.57 per share3.51
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/A$3.32 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
NexImmune, Inc. stock logo
NEXI
NexImmune
-$32.34M-$30.89N/AN/AN/A-247.17%-167.39%5/20/2024 (Estimated)

Latest INNVD, CYCC, LCI, and NEXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
NexImmune, Inc. stock logo
NEXI
NexImmune
N/A-$4.99-$4.99-$4.99N/AN/A
3/19/2024Q4 2023
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$6.35-$6.23+$0.12-$6.23N/A$0.03 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
0.91
0.91
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
NexImmune, Inc. stock logo
NEXI
NexImmune
N/A
1.06
1.06

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
10.38%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
NexImmune, Inc. stock logo
NEXI
NexImmune
9.85%

Insider Ownership

CompanyInsider Ownership
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
8.47%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
16.43%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
NexImmune, Inc. stock logo
NEXI
NexImmune
19.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2,0181.32 million1.21 millionOptionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
NexImmune, Inc. stock logo
NEXI
NexImmune
221.37 million1.11 millionNot Optionable

INNVD, CYCC, LCI, and NEXI Headlines

SourceHeadline
Spyre Therapeutics (NASDAQ:SYRE) and NexImmune (NASDAQ:NEXI) Head to Head ContrastSpyre Therapeutics (NASDAQ:SYRE) and NexImmune (NASDAQ:NEXI) Head to Head Contrast
americanbankingnews.com - May 2 at 2:22 AM
Nanoengineering Approaches to the Design of Artificial Antigen-presenting CellsNanoengineering Approaches to the Design of Artificial Antigen-presenting Cells
medscape.com - April 20 at 3:38 PM
NEXI Stock Earnings: NexImmune Reported Results for Q4 2023NEXI Stock Earnings: NexImmune Reported Results for Q4 2023
investorplace.com - April 17 at 1:03 AM
Acute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsightAcute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsight
theglobeandmail.com - April 16 at 12:07 AM
Portage mulls company closure, pauses enrolment for lead clinical programmePortage mulls company closure, pauses enrolment for lead clinical programme
msn.com - April 15 at 7:00 PM
Xilio fires 21% of its workforce and reprioritises pipelineXilio fires 21% of its workforce and reprioritises pipeline
msn.com - April 2 at 4:55 PM
Investors grapple with more choices in big year for pharma fundraisingInvestors grapple with more choices in big year for pharma fundraising
pharmaceutical-technology.com - March 20 at 7:15 PM
NexImmune Announces New Offerings in Recent Press ReleaseNexImmune Announces New Offerings in Recent Press Release
msn.com - February 7 at 3:58 PM
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
markets.businessinsider.com - February 6 at 9:13 PM
NexImmune Secures Funding Through Equity and Warrant SalesNexImmune Secures Funding Through Equity and Warrant Sales
msn.com - February 6 at 8:39 AM
NexImmune Ends Stock Sale Agreement, Raises $5.1 MillionNexImmune Ends Stock Sale Agreement, Raises $5.1 Million
msn.com - February 3 at 3:23 PM
NexImmune slips after securities offeringNexImmune slips after securities offering
msn.com - February 2 at 6:34 PM
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
finance.yahoo.com - February 2 at 6:34 PM
NexImmune, Inc. Common Stock (NEXI)NexImmune, Inc. Common Stock (NEXI)
nasdaq.com - January 13 at 9:31 PM
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential LiquidationNexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation
investorplace.com - January 9 at 1:04 PM
Neximmune Inc (NEXI) Took The Aerial Rout In The Pre-Market SessionNeximmune Inc (NEXI) Took The Aerial Rout In The Pre-Market Session
knoxdaily.com - January 4 at 10:20 AM
NexImmunes future in limbo as Gaithersburg biotech extends liquidation voteNexImmune's future in limbo as Gaithersburg biotech extends liquidation vote
bizjournals.com - December 26 at 2:54 PM
NexImmune: Submission Of Matters To A Vote Of Security Holders, Other EventsNexImmune: Submission Of Matters To A Vote Of Security Holders, Other Events
cbonds.com - December 24 at 8:51 AM
NexImmune, Inc. (NEXI) Stock Price, News, Quote & History - Yahoo FinanceNexImmune, Inc. (NEXI) Stock Price, News, Quote & History - Yahoo Finance
ca.finance.yahoo.com - December 10 at 8:27 PM
NexImmune: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of ListingNexImmune: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing
cbonds.com - December 3 at 8:08 AM
NEXI Stock Halted: What’s Going on With NexImmune Shares Today?NEXI Stock Halted: What’s Going on With NexImmune Shares Today?
investorplace.com - December 1 at 2:04 PM
Why Is NexImmune (NEXI) Stock Up 353% Today?Why Is NexImmune (NEXI) Stock Up 353% Today?
investorplace.com - December 1 at 9:12 AM
NexImmune Inc Ordinary Shares NEXINexImmune Inc Ordinary Shares NEXI
morningstar.com - November 23 at 8:51 PM
Gaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employeesGaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employees
bizjournals.com - November 8 at 6:33 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cyclacel Pharmaceuticals logo

Cyclacel Pharmaceuticals

NASDAQ:CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Innovus Pharmaceuticals logo

Innovus Pharmaceuticals

OTCMKTS:INNVD
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Lannett logo

Lannett

NYSE:LCI
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.
NexImmune logo

NexImmune

NASDAQ:NEXI
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.